Skip to main content

Alternative Testing Methods

Alternative Testing Methods

The new biotech horizon with an expected 10% annual growth from 2022 to 2025.

After experiencing a particularly high growth rate in 2021, the biotech sector is expected to continue growing at a compound annual growth rate of almost 16% until 2028, reaching an expected market size of $2.44 trillion that same year. New government policies, higher investment prospects and, above all, the expected market entry of multiple innovative products are going to be the sector drivers for the next lustrum.

Alternative Testing Methods: The new biotech milestone

A rising horizon in biotech has been Alternative Testing Methods for substance and drug discovery. From in vitro methods to computer-modeling techniques, these new technologies aim to reduce time and development costs in comparison to traditional animal testing standards, known to be highly resource-consuming, unethical and facing multiple pipeline drawbacks hindering R&D.

In The Principles of Humane Experimental Technique, Russell and Burch (1959) firstly introduced the consideration for a more ethical and sustainable biological testing throughout what they defined as the 3Rs: Replace, Reduce, Refine. Since then, the 3Rs principle has become what nowadays are known as Alternative Testing Methodologies. Today, the drug discovery sector is experiencing a decreasing in efficiency, outstanding the need for cost-effective and reduced time-bounded testing alternatives to boost and speed-up R&D for unmet medical and consumer needs.

Nonetheless, the gap between traditional animal testing and in vitro cellular models is still a reality.

While toxicology and substance efficacy tests have been successfully performed using in vitro systems, more complex assays at the whole-organism level are still an arduous problematic for this type of methodologies. 

An emerging alternative is the use of 3D cell models or small organisms as the founders of Nagi Bioscience explain in an interview for Radio Télévision Suisse (RTS) about how they obtain organism-level data using microscopic worms (C. elegans) for biological testing:

RTS Ici la Suisse. Les alternatives à l'expérimentation animale

NAMs and the Alternative Testing Methods Market

The term New Approach Methodologies (NAMs) refers to any methodology and/or technology that can be used for data collection to evaluate chemical hazard and risk assessment without using traditional animal testing (EPA, 2021). Cosmetics, agrochemical substances, food additives or medical drugs are some of the multiple products that can be tested with NAMs at the pre-clinical trial stage.

The Business Research Company described in 2021 the exponential adoption of NAM technologies for pre-clinical research due to the risk/benefit balance: high probability of pre-clinical trial failure and cost-effective assays. The same report claimed an expected CAGR of 9.08% in the global non-animal alternative testing market resulting in a total of $1.78 billion for this current year 2022. Despite the traditional animal testing sector reporting a higher market share ($10.74 billion in 2019), its expected compound annual growth rate is estimated to be 4.27% during 2019-2025 and 2.46% between 2025 and 2035.

The expected growth of NAMs in the next decade is highly supported by governmental institutions all around the globe such as USA, Denmark, Switzerland, Brazil, Australia or China, throughout the funding of research programs and the implementation of new legislative measures regarding substance testing promoting alternative testing.

While the animal testing market is experiencing a steady downturn growth, the Alternative Testing Methodologies are progressively absorbing market share with a expected CARG of 10.40% between 2019 and 2025 and a 11.62% growth rate during 2025-2035.
Non-animal Alternative Testing Market  Size (in $ Billion )

Alternative Testing Market estimation

All in all, alternative testing methods constitute a highly effective, sustainable and fast option for drug and other substances’ hazard assessment with an already promising exponential market growth becoming the next star in the biotech landscape.

Do you want to know more?

Along with other Swiss Startups, Nagi Bioscience is heading the transition to the new era of biological testing: scalable, efficient, ethical, sustainable and animal-free.

Check out here Nagi's pioneer Organism-on-Chip and its in vivo testing at the in vitro scale technology.

Video Venture Kick. Alternative Testing start ups


Did you like it? Share it!

Start your next project with us and join a new era in biological testing

Contact one of our experts today